Login / Signup

Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.

Thomas NyströmJohan BodegardDavid NathansonMarcus ThuressonAnna NorhammarJan W Eriksson
Published in: Diabetes, obesity & metabolism (2017)
Novel oral GLD treatment was associated with lower risk of all-cause mortality, CVD and severe hypoglycaemia compared with insulin treatment. Dapagliflozin was associated with a lower risk of both all-cause mortality and CVD, whereas DPP-4 inhibitor treatment was only associated with lower risk of all-cause mortality.
Keyphrases
  • type diabetes
  • cardiovascular events
  • coronary artery disease
  • blood pressure
  • combination therapy
  • metabolic syndrome
  • adipose tissue
  • insulin resistance
  • skeletal muscle
  • drug induced
  • weight loss